Xxxxxxxxx, M. Do you really need a blockchain? xxxxx://xxxxxxx.xxx/ xxxxxxxxxxxxx/status/787760892783894528
Xxxxxxxxx, M. H. et al. Fibroblasts genetically modified to produce nerve growth factor induce robust neuritic ingrowth after grafting to the spinal cord. Exp Neurol 126, 1-14 (1994).
Xxxxxxxxx, M. H. et al. NT-3 gene delivery elicits growth of chronically injured corticospinal axons and modestly improves functional deficits after chronic scar resection. Exp Neurol 181, 47-56 (2003).
Xxxxxxxxx, M. S., Xxx, P. C., Xxxxxxxx, X. X., Xxxxxx, C. N. & Xxxxxxxxx-Xxxx, B. Telavancin in Hospital-Acquired and Ventilator-Associated Pneumonia (HAP/VAP) Caused by Staphylococcus aureus: Post Hoc Analysis of 2 Randomized, Controlled Trials. Infect. Dis. Ther. 8, 445–452 (2019). 87. Xxxx, X. X., Xxxxxxx, X., Xxxxxx, X., Xxxxxxx, X. X., Xxxx, X. & Xxxxxxxx, S. Pharmacokinetics, serum inhibitory and bactericidal activity, and safety of telavancin in healthy subjects. Antimicrob. Agents Chemother. 49, 195–201 (2005). 88. Xxxx, X. X., Xxxxxxxx, X. X., Xxxx, X. X. & Xxxxxxxx, M. R. Multiple-dose pharmacokinetics of intravenous telavancin in healthy male and female subjects. J. Antimicrob. Chemother. 62, 780–783 (2008). 89. Xxxxxxx, X. X., Xxxx, X. X. & Xxxxxxxx, X. X. Pharmacokinetics of intravenous telavancin in healthy subjects with varying degrees of renal impairment. Eur. J. Clin. Pharmacol. 71, 707–714 (2015). 90. Xxxxxxxx, X. X. The ATTAIN trials: Efficacy and safety of telavancin compared with vancomycin for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia. Future Microbiol. 9, 281–289 (2014). 91. Xxxxxxxxx, X. X., Xxxxx, X., Xxxxxxxx, X., Xxxxx, X., Xxxxxxxx, X., Xxxxxxxxx, X., Xxxxxxx, P., Xxxxxx, M., Xxxxxx, V. & Xxxxxxx, G. A40926, a new glycopeptide antibiotic with anti-Neisseria activity. Antimicrob. Agents Chemother. 31, 1961–1966 (1987). 92. Xxxxxxxxx, X. & Xxxxxxxxx, X. X. Origin, structure, and activity in vitro and in vivo of dalbavancin.
Xxxxxxxxx, M. A.; Xxxxxxxx, X.X.; Xxxxxxxx, X.X. Viral Vectors for Gene Therapy: Translational and Clinical Outlook. Annu. Rev. Biomed. Eng. 2015, 17, 63–89, doi:10.1146/annurev-bioeng-071813-104938.
Xxxxxxxxx, M. E. (2006). Multilevel component analysis. British Journal of Mathematical and Statistical Psychology, 59, 301-320.
Xxxxxxxxx, M. I.T. and HARVARD, in their sole discretion, may choose at any time following the initiation of such PATENT CHALLENGE to grant one or more licenses to third parties under the PATENT RIGHTS, including without limitation, to develop, make, have made, use, sell, offer to sell, lease, and import LICENSED PRODUCTS in the FIELD in the TERRITORY; and to develop and perform LICENSED PROCESSES in the FIELD in the TERRITORY.
Xxxxxxxxx, M. I.T. and HARVARD shall use reasonable efforts to maintain in confidence all CONFIDENTIAL INFORMATION (as defined below) of COMPANY and shall use reasonable efforts to not use or disclose such CONFIDENTIAL INFORMATION, except as expressly authorized by this Agreement. “CONFIDENTIAL INFORMATION” shall mean all information and reports labeled “confidential” and due to XXXXXXXXX (or, if applicable, M.I.T. or HARVARD) under this Agreement, including without limitation reports due under Article 5 and any terms of sublicense agreements disclosed pursuant to Section 2.4(a). In addition, the terms of this Agreement shall be deemed to be CONFIDENTIAL INFORMATION. The non-disclosure and non-use obligations set forth above shall not apply to any information to the extent that (a) XXXXXXXXX, M.I.T. or HARVARD can show by written record that it possessed the information prior to its receipt from COMPANY; (b) the information was, at the time of disclosure, available to the public or became so through no fault of XXXXXXXXX, M.I.T. or HARVARD; or (c) the information is subsequently disclosed to XXXXXXXXX, M.I.T. or HARVARD free of any obligations of confidentiality by a third party that has the right to disclose it. Notwithstanding any other provisions of this Section 15.9, XXXXXXXXX, M.I.T. and HARVARD may disclose CONFIDENTIAL INFORMATION of COMPANY (i) on a need-to-know basis and in connection with the performance of their respective obligations and/or exercise of their respective rights under this Agreement, to its employees, consultants, or agents provided that such individuals or entities are bound by non-disclosure and non-use obligations at least equivalent in scope to those set forth in this Section 15.9; (ii) in confidence to its trustees, directors and professional advisors; and (iii) to the extent that such disclosure is required by a court order, or in order to comply with applicable laws or regulations, but provided that XXXXXXXXX, M.I.T. and HARVARD will, except where impracticable, give reasonable advance notice to COMPANY of such required disclosure and use efforts to secure, or to assist the other party in securing, a protective order relating to, or confidential treatment of, such information.
Xxxxxxxxx, M. D., P.C. & Associates to discuss my medical care with Print name of individual Relationship
Xxxxxxxxx, M. (eds.). Selected Proceedings of the 36th Annual Conference on African Linguistics. Cascadilla Proceedings Project, Somerville, MA, p. 60-65, 2006. XXXX, X. 2003. Serial verb constructions in Degema, Nigeria. African Study Monographs 24: 271– 289. XXXXX, X. Conceptual issues in the comparative study of the Bantu verb stem. Amsterdam Studies in the Theory and History of Linguistic Science Series, 4 1993. XXXXX, L et. al. Niger-Congo Linguistic Feature and Typology. In Xxxxx, X. The Cambridge Handbook of African Linguistics. New York: Cambridge University Press, p. 191- 245, 2019. XXXXXX, X. 1991. Some Issues in Verb Serialization. In Xxxxxx Xxxxxxxx (ed.). Grammatical, comparative and cognitive approaches. Amsterdam: Xxxx Xxxxxxxxx Publishing Company. XXXX, X. A (tentative) verb slot system for Shona. Unpublished paper presented at the University of Gothenburg, 1999b. XXXXXXXX, X. Tense parameters and serial verbs. University of Boston. 2005. xxx.xxxxxx.xx.xxx/xxxxxxxx/svc.pdf (Accessed on 04/03/2020). XXXXX, X. The categorical status and functions of Auxiliaries in Shona. Unpublished PhD dissertation. University of Zimbabwe, 2002. XXXXXXXX, X., Agreement Properties and Word Order in Comparative Bantu. ZAS Papers in Linguistics 43, 2006. p. 161–188.
